Bionomics Australian S.E.

Equities

BNO

AU000000BNO5

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 11:40:06 24/08/2023 am IST			5-day change	1st Jan Change
0.01 ^AUD	-.--%		-.--%	-.--%

21/03	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	CI
15/03	Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Bionomics Limited : IRONWOOD AND BIONOMICS ANNOUNCE AGREEMENT

January 05, 2012 at 04:11 am IST

MarketScreener.com By

FOR IMMEDIATE RELEASE Ironwood Contact: Bionomics Contact: Susan Brady Dr Deborah Rathjen Corporate Communications CEO & Managing Director

617.621.8304 +61 8 8354 6101 sbrady@ironwoodpharma.com drathjen@bionomics.com.au

IRONWOOD PHARMACEUTICALS AND BIONOMICS ANNOUNCE COLLABORATION, RESEARCH, AND LICENSE AGREEMENT Companies to Collaborate on Central Nervous System Disorder Opportunity

CAMBRIDGE, Mass. and ADELAIDE, Australia January 5, 2012 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Bionomics Limited (ASX: BNO) today announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics' investigational anti

Latest news about Bionomics

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	21/03	CI
Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	15/03	CI
Wall Street Set to Open Higher in Monday Trading Ahead of Economic Indicators Data	22/01	MT
US Futures Poised to Open Week Higher, Leading Economic Indicators on Tap	22/01	MT
Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023	28/11	CI
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%	11/11	DJ
Bionomics to Advance Social Anxiety Disorder Treatment Into Phase 3 Studies After End-of-Phase 2 Meeting With US FDA	16/23/16	MT
Bionomics Limited Announces Successful and Favorable Outcomes of an End-Of-Phase 2 Meeting Meeting with the U.S. Food and Drug Administration	16/23/16	CI
Bionomics Trades 1.8% Lower in Premarket Activity Tuesday After Surging 46% in Previous Regular Trading Session	03/23/03	MT
Top Premarket Gainers	02/23/02	MT
Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/23/29	CI
Bionomics Retreats 15% Premarket Friday After Surging 244% in Previous Trading Session Following Positive Phase 2b Data	29/23/29	MT
Bionomics Sinks 12% After Hours Thursday Following 244% Surge in Previous Regular Trading Session on Positive Phase 2b Trial Results	29/23/29	MT
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	29/23/29	MT
Top Midday Gainers	28/23/28	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	28/23/28	MT
Sector Update: Health Care	28/23/28	MT
Biometrics Soar After Company Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms	28/23/28	MT
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected	28/23/28	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	28/23/28	MT
Sector Update: Health Care	28/23/28	MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	28/23/28	MT
Bionomics Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms	28/23/28	MT
Top Premarket Gainers	28/23/28	MT
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	28/23/28	CI

Chart Bionomics

Duration

Period

More charts

Company Profile

Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the Î±7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its Î±7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimerâs disease and other central nervous system conditions. The Companyâs CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.

Sector

Biotechnology & Medical Research

Calendar

21/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bionomics

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.265 AUD

Average target price

15.3 AUD

Spread / Average Target

+1,109.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr
INSMED INCORPORATED	+77.64%	887.31Cr

Bio Therapeutic Drugs